Compare Aspen Aerogels Inc (ASPN) vs Novavax Inc (NVAX) Price & Performance

ASPN trades at $6.14, down 2.38% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $389.55 million in 2025, though Q2 2026 revenue beat estimates and Q3 guidance suggests recovery. Analyst consensus is strongly bullish with 82.61% buy ratings.

Outlook hinges on execution of revenue growth and margin improvement, particularly in thermal barrier segments. Risks include persistent negative profitability, high cash burn, and competitive pressures in EV materials. The stock offers speculative upside if operational targets are met.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.